文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

多靶点胸部立体定向体部放疗的毒性与疗效

Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-08

回顾性分析2012至2021年间190例接受≥2个胸部靶点SBRT(多靶点胸部SBRT)的患者,中位随访19.7个月,临床显著放射性肺炎(CSRP)累积发生率6个月5.3%、12个月7.6%,2年局部失败累积发生率10.5%,多因素分析示较高肺V35Gy与CSRP相关。

要点

  • 190例(481个病灶)多靶点胸部SBRT,14例(7.4%)发生CSRP,其中5例需吸氧。
  • CSRP累积发生率6个月5.3%、12个月7.6%;2年局部失败累积发生率10.5%。
  • 多因素分析示较高肺V35Gy是CSRP的统计学显著预测因素(HR 2.59,P=.02)。

核心结论

  • 在一个较大的机构系列中,多靶点胸部SBRT的CSRP和局部失败率均较低;优化计划以降低肺V35Gy可能降低CSRP风险。

研究设计与样本

  • 回顾性分析2012年至2021年间接受SBRT的≥2个胸部靶点(间隔≤1年)的患者,共190例、481个病灶,中位随访19.7个月。

主要发现

  • SBRT指征为寡转移70例(36.8%)、寡进展62例(32.6%)、原发性肺癌根治性治疗37例(19.5%)、转移性进展优势区域控制21例(11.0%)。
  • 照射肿瘤数目2至7个,大多数SBRT疗程为同步实施(88.2%)。
  • 14例(7.4%)发生CSRP,其中5例需吸氧;CSRP累积发生率6个月5.3%、12个月7.6%。
  • 2年局部失败累积发生率为10.5%,2年启动或更换系统性治疗累积发生率为41.1%。
  • 中位无进展生存期为11.8个月,中位总生存期为51.3个月。

临床怎么用

  • 作者认为,优化计划以降低肺V35Gy可能降低CSRP风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With the increasing use of stereotactic body radiation therapy (SBRT) for primary and metastatic cancer, use of multitarget thoracic (MTT) SBRT is rising. Given the limited safety and efficacy data, we report the experience of this strategy from a large academic center. METHODS AND MATERIALS: Between 2012 and 2021, patients who received SBRT for ≥2 thoracic targets separated by ≤1 year were retrospectively reviewed. The primary endpoint was clinically significant radiation pneumonitis (CSRP) requiring steroids, oxygen, or intubation. Secondary endpoints included local failure (LF), initiation or change of systemic therapy (ICST), progression-free survival, and overall survival. Competing risk analysis was used to evaluate the cumulative incidence of CSRP, LF, and ICST. Univariate and multivariable analyses were performed to look for clinical and dosimetric predictive factors of CSRP and LF. RESULTS: One hundred ninety patients (481 lesions) were treated with MTT SBRT with a median follow-up of 19.7 months. Indications for SBRT were oligometastases (n = 70; 36.8%), oligoprogression (n = 62; 32.6%), curative intent in patients with primary lung cancer (n = 37; 19.5%), and control of dominant areas of metastatic progression (n = 21; 11.0%). The number of irradiated tumors ranged from 2 to 7 and the majority of SBRT courses were delivered simultaneously (88.2%). Overall, 14 patients (7.4%) had CSRP, with 5 cases requiring oxygen. The cumulative incidence of CSRP at 6 and 12 months was 5.3% and 7.6%, respectively. The cumulative incidence of LF at 2 years was 10.5%. The cumulative incidence of ICST at 2 years was 41.1%. Median progression-free survival was 11.8 months and median overall survival was 51.3 months. On multivariable analysis, a higher lung V35Gy (hazard ratio, 2.59; P = .02) was a statistically significant predictor of CSRP and colorectal histology predicted for higher LF (hazard ratio, 2.12; P = .02). CONCLUSIONS: In one of the largest institutional series of MTT SBRT, rates of CSRP and LF were low. Optimizing plans to lower the lung V35Gy may decrease the risk of CSRP.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nguyen EK, Poon I, Ung YC, et al. Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 36368432. doi:10.1016/j.ijrobp.2022.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。